News Quantified

PVLA – palvella therapeutics, inc. (US:NASDAQ)

Palvella Therapeutics: Phase 2 Success De-Risks 2026 Catalyst [Seeking Alpha]

High Analyst Confidence on Palvella Therapeutics (PVLA) Following Encouraging Phase 2 Data for QTORIN Rapamycin [Yahoo! Finance]

Assessing Palvella Therapeutics' Valuation After Its Rare Disease Momentum-Driven Surge in 2024 [Yahoo! Finance]

Palvella Therapeutics price target raised to $200 from $120 at Oppenheimer [Yahoo! Finance]

Palvella Therapeutics (NASDAQ:PVLA) was given a new $204.00 price target on by analysts at Canaccord Genuity Group Inc..

Live Event: Join our next subscriber-only event: "The Data Driven Investor"

Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

52 Week High	{{GetCompanyStockInfo.Week52HighValue}} {{GetCompanyStockInfo.Week52HighDate}}
52 Week Low	{{GetCompanyStockInfo.Week52LowValue}} {{GetCompanyStockInfo.Week52LowDate}}

Today’s Volatility	{{VolatilityStr}}
20 Day Volatility	{{Volatility20Str}}

Open	{{GetCompanyStockInfo.Open}}
Prior Close	{{GetCompanyStockInfo.PriorCloseValue}} {{GetCompanyStockInfo.PriorCloseDate}}